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Abstract
Background: More than 15 million people worldwide have rheumatic fever (RF) and rheumatic heart disease due
to RF. Secondary prophylaxis is a critical cost-effective intervention for preventing morbidity and mortality related
to RF. Ensuring adequate adherence to secondary prophylaxis for RF is a challenging task. This study aimed to
describe the rates of recurrent episodes of RF, quantify adherence to secondary prophylaxis, and examine the
effects of medication adherence to the rates of RF in a cohort of Brazilian children and adolescents with RF.
Methods: This retrospective study took place in the Pediatric Rheumatology outpatient clinic at a tertiary care
hospital (Instituto de Puericultura e Pediatria Martagão Gesteira) in Rio de Janeiro, Brazil, and included patients with
a diagnosis of RF from 1985 to 2005.
Results: 536 patients with RF comprised the study sample. Recurrent episodes of RF occurred in 88 of 536 patients
(16.5%). Patients with a recurrent episode of RF were younger (p < 0.0001), more frequently males (p = 0.003), and
less adherent (p < 0.0001) to secondary prophylaxis than patients without RF recurrence. Non-adherence to
medication at any time during follow-up was detected in 35% of patients. Rates of non-adherence were higher in
the group of patients that were lost to follow-up (42%) than in the group of patients still in follow-up (32%)
(p = 0.027). Appointment frequency was inadequate in 10% of patients. Higher rates of inadequate appointment
frequency were observed among patients who were eventually lost to follow-up (14.5%) than in patients who
were successfully followed-up (8%) (p = 0.022). 180 patients (33.5%) were lost to follow up at some point in time.
Conclusions: We recommend implementation of a registry, and a system of active search of missing patients in
every service responsible for the follow-up of RF patients. Measures to increase adherence to secondary prophylaxis
need to be implemented formally, once non-adherence to secondary prophylaxis is the main cause of RF
recurrence. Detection of irregularity in secondary prophylaxis or in appointments should be an alert about the
possibility of loss of follow-up and closer observation should be instituted.
Background
In developing countries, rheumatic fever (RF) is the pre-
dominant cause of acquired childhood cardiopathy [1,2].
More than 15 million people worldwide have RF and
rheumatic heart disease (RHD) due to RF, with nearly a
quarter million deaths occurring annually due to this
condition [3-6]. The prevalence of RHD is estimated to
be higher in developing than in developed countries,
ranging from 24/1,000 to 0.3/1,000, respectively [3,6,7].
It is estimated that 95% of the cases of RHD and deaths
related to this disease occur in developing countries [8].
Moreover, significant costs are associated with the treat-
ment of RHD, including heart valve replacement [9].
The severity and prognosis of RHD depends on the
extent of cardiac involvement and the frequency of
recurrent events [6,10-13]. The risk of RF after an
untreated group A beta-hemolytic streptococcal
(GABHS) infection in healthy children is around 3%
[4,6]; however in children with a previous episode of RF,
this risk increases to more than 50%, emphasizing the
importance of secondary prophylaxis [14]. Secondary
prophylaxis, including the use of benzathine penicillin
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G, is therefore a critical cost-effective intervention for
preventing morbidity and mortality related to RF
[3,6,8,9,15,16].
However, ensuring adequate adherence to secondary
prophylaxis for RF has been a challenging task, particu-
larly in adolescents; as with most chronic treatments,
adherence is usually poor [17-20]. There is no reliable
data available with regards to adherence to secondary
prophylaxis and the rates of recurrent RF in many
developing countries, including Brazil.
The objectives of this large observational study were
to describe the rates of recurrent episodes of RF, quan-
tify adherence to secondary prophylaxis, and examine
the effects of medication adherence to the rates of RF in
a cohort of Brazilian children and adolescents with RF.
Methods
This retrospective study took place in the Pediatric
Rheumatology outpatient clinic at a tertiary care hospital
(Instituto de Puericultura e Pediatria Martagão Gesteira)
in Rio de Janeiro, Brazil, and included patients with a
diagnosis of RF from 1985 to 2005. Information was
retrieved from patients’ medical records, using a struc-
tured data collection sheet.
We identified 548 cases of children and adolescents
with a diagnosis of RF. All patients who fulfilled the
Jones criteria [12] for the diagnosis of RF were included;
12 patients were excluded from the present analysis
because they did not return to the clinic after their first
appointment.
Patients were classified as “adherent” to therapy when
they did not skip or delay more than one dose of ben-
zathine penicillin G during a 6-month period (interval
between appointments). If more than one dose of ben-
zathine penicillin G was delayed or missed during this
period, patients were classified as “non-adherent”. Admi-
nistered doses of benzathine penicillin G were recorded
on a card given to all patients with RF in Brazil. The
classification of adherence contained in the outpatient
charts, was primarily based on this card, as well as self-
reports when patients had forgotten the card in a speci-
fic appointment.
Appointment frequency was considered adequate if
the interval between visits was less than 9 months. The
interval between appointments in our clinic is normally
6 months for RF patients who are being followed for
secondary prophylaxis. If patients had their appoint-
ments in intervals longer than 9 months, appointment
frequency was considered inadequate. When patients
did not return for an appointment for more than
18 months, they were considered lost to follow-up.
We classified a RF episode as recurrent according to
standardized World Health Organization criteria [12,21].
The Research Ethics Committee of Instituto de Pueri-
cultura e Pediatria Martagão Gesteira approved this
project.
Statistical analyses
The rates of recurrence, non-adherence to secondary
prophylaxis, and inadequate frequency to appointments
were calculated for the total group, as well as for
patients who were successfully followed-up, and for
those that were lost to follow-up, separately. Differences
in the characteristics of patients who did and did not
have a recurrent episode of RF were examined with
regards to age, sex, adherence to prophylaxis, frequency
of follow-up appointments and follow-up status. Fisher’s
exact test was used to examine differences between
these 2 comparison groups with regards to categorical
variables whereas the Student T-test was used to com-
pare differences in various continuous variables. Statisti-
cal significance was established with an alpha of 0.05.
Results
A total of 536 patients with RF comprised the study sam-
ple. The average age of the study sample was 13 (± 3.9)
years and 53% were girls.
Recurrent episodes of RF occurred in 88 of 536
patients (16.5%). Patients with a recurrent episode of RF
were younger, more frequently males, and less adherent
to secondary prophylaxis than patients without RF
recurrence (table 1). There was a trend to a higher rate
of adequate frequency to appointments in the group of
patients that did not have a recurrence (p = 0.07). There
was not a significant difference between patients who
did or did not have a recurrence in relation to loss of
follow-up. Within patients who had a recurrence 54.5%
were non-adherent to secondary prophylaxis. 31% had a
recurrence because prophylaxis was not prescribed, as
those patients had not had the diagnosis of RF in a pre-
vious episode due to lack of sufficient criteria for the
diagnosis. 14.5% of the patients who had recurrences
reported adherence to prophylaxis. As expected, non-
adherence to secondary prophylaxis had a significant
association with recurrences of RF (p < 0.0001).
Non-adherence to medication at any time during fol-
low-up was detected in 35% (188 out of 536) of patients.
Rates of non-adherence were higher in the group of
patients that were lost to follow-up (42%) than in the
group of patients still in follow-up (32%) (table 2). The
mean age of non-adherent patients was 14.5 years.
Appointment frequency was inadequate in 10% of
patients. Higher rates of inadequate appointment
frequency were observed among patients who were
eventually lost to follow-up (14.5%) than in patients who
were successfully followed-up (8%) (table 2).
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One hundred eighty patients (33.5%) were lost to fol-
low up at some point in time. The time between the first
appointment and the last in this group of patients ranged
from 1 month to 13.4 years. The mean time of follow-up
in this group was 6.8 years. There were no significant dif-
ferences in either age or sex in the group lost to follow-
up and the group that was successfully followed-up.
Discussion
Recurrences of RF are directly related to morbidity,
mortality and disease progression [22]. 16.5% of patients
in our study had a recurrent episode of RF, however
recurrence was found in 0.9% of patients in a rural dis-
trict in north of India [19], and in 0.4% in a study invol-
ving 16 developing countries [23]. Rates similar to ours
were detected in Chile (17%) in 1993 [24]. In Alexandria
(Egypt), in 1998, RF recurrence was found to be 37.3%
and the risk factors implied were: living in rural and
semi-urban areas, and lack of adherence to secondary
prophylaxis [25]. In Australia the implementation of a
RF register was associated with a decrease in recurrence
rates from 28% (in 1998) to 16% (in 1999) [14]. In con-
trast to our results, increase in age has been identified
as a predictor of RF recurrence in a cross-sectional
study in Nepal [2].
In our population, recurrences were associated to non-
adherence to secondary prophylaxis in 54.5% of cases.
However, in 31% secondary prophylaxis was not pre-
scribed because they did not have a diagnosis of RF on
a previous episode, or because prophylaxis was withheld
in patients who did not meet Jones criteria. These
patients had a previous suspicious episode that did not
fulfill Jones criteria, and then presented with a recur-
rence that made the diagnosis possible, according to the
mentioned criteria. After the diagnosis was definitely
established, secondary prophylaxis was prescribed. A
common and preventable error detected among patients
in our study population was precocious use of non-ster-
oidal anti-inflammatory (NSAID) drugs, prescribed
before they reached our clinic. This may prevent the
natural evolution of polyarthritis, making diagnosis diffi-
cult or even impossible, preventing adequate manage-
ment of patients with secondary prophylaxis and letting
them exposed to recurrences [6,25]. This issue has been
described in other high-incidence populations [26], and
that’s why the 2006 New Zealand guidelines for RF con-
sider aseptic monoarthritis as a major criterion when
there is a history of prior NSAID use [6].
After each revision of Jones criteria, specificity
increased and sensitivity decreased [6]. This occurred
because of the decrease of RF incidence in developed
countries [3]. Jones criteria should be a guide to help
physicians but should not be strictly applied and sub-
stitute clinical judgment, as it could result in under-
diagnosis of RF in countries where it is still highly
incident, as in Brazil [6,13,21,26]. In countries where
RF is still endemic or epidemic the risk associated with
an eventual recurrence with possible development or
aggravation of RHD, surpasses consequences of a false
diagnose [3].
Non-adherence to secondary prophylaxis was 35% in the
total sample of patients (536). In other studies this rate
varies from 10% to 65.7% [5,14,19,23,25,27-32]. Although
high, the rate reported in our center corresponds to rates
found in other centers. Among patients lost to follow-up,
42% were non-adherent, compared to 32% in the group
successfully followed-up (p = 0.027). There is a significant
difference within the two groups, and non-adherence to
secondary prophylaxis might be used as a precocious sign
of the possibility of loss of follow-up.
Table 1 Characteristics of patients with and without recurrent episodes of RF
Patients with recurrent episodes of RF
(n = 88)
Patients without recurrent episodes of RF
(n = 448)
P value
Age (median, years) 9 14 < 0.0001
Sex (female) 38% 56% 0.003
Non-adherence 54.5% 20% < 0.0001
Adequate frequency to appointments 79% 90% 0.07
Lost to follow-up 37.5% 29% 0.14
Table 2 Recurrence, non-adherence, and inadequate frequency to appointments in the total sample and subgroups
Patients successfully
followed-up (n = 356)
N (%)
Patients lost to
follow-up (n = 180)
N (%)
p-value Total
(% in the total group)
Recurrences 55 (15%) 33 (18%) 0.14 88 (16.5%)
Non-adherence 113 (32%) 75 (42%) 0.027 188 (35%)
Inadequate frequency to appointments 28 (8%) 26 (14.5%) 0.022 54 (10%)
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Factors related to the lack of adherence in other stu-
dies were: lower education of the parents, living in rural
or semi-urban areas, low parental knowledge about the
disease and dissatisfaction of the family with care [25].
As our study was retrospective, we could not analyze
the causes of lack of adherence.
To guarantee higher adherence to prophylaxis and
appointments, implementation of education and aware-
ness strategies for patients and families may be a solu-
tion. According to the KAP (knowledge, attitude,
practice) model of promotion of health, knowledge is
necessary in order to change individuals’ behaviors
[17,20]. Other effective strategies for preventing dis-
continuation of follow-up and of secondary prophylaxis
are notification of RF cases, and implementation of
mechanisms to identify and localize patients who have
been missing appointments [15,30]. Counseling about
the relevance of adherence to therapy, how to organize
administration of medication, remembering notes
about appointments, rewards to the efforts of patients
in following the prescribed regimen, and stimulus
of the support of family and friends are effective
interventions to long course treatments [14]. These
interventions might represent hard work, but they are
cost-effective [30,33]. They have been associated to
enhancement in adherence to long course treatments
in 50%; and among those, 44.5% had improvement of
prognosis [33]. Training of health personnel, health-
care education, community involvement, and epide-
miological surveillance were part of the Cuban project
that significantly reduced first and recurrent attacks of
RF, severity of RHD, and direct costs of managing the
disease, as well as increased compliance with secondary
prophylaxis [5].
Inadequate frequency to appointments was found in
10% in the total sample of patients. This rate was 16%
in a study in a rural community in north of India [19].
The inadequate frequency to appointments was 8% in
the group who was successfully followed-up and 14.5%
in the group that was lost to follow-up. There is a sig-
nificant difference (p = 0.022) between the two
groups, which might indicate irregularity in appoint-
ments as an early sign of the possibility of loss of fol-
low-up.
Inadequate frequency to appointments is correlated to
lower indices of adherence to treatment prescribed and it
is the first sign of possible discontinuation of treatment,
which is the most severe form of lack of adherence [17].
One hundred eighty patients (33.5%) were lost to fol-
low-up. In another study in Rio de Janeiro, Brazil, at
Hospital Universitário Antônio Pedro, 55% of patients
were lost to follow-up in a group treated with parenteral
secondary prophylaxis and 10% in another group treated
with oral secondary prophylaxis [34].
Patients who were lost to follow-up in our center were
not tracked because of the lack of a recall system. How-
ever, a rate of loss of follow-up of one third is signifi-
cant and justifies the implementation of such a system.
It would have a relatively low cost for the health service
but a high possible repercussion in patients’ morbidity
and mortality.
This study has some limitations, as the impossibility to
establish the causes of non-adherence to secondary pro-
phylaxis, since it was retrospective; as well as the lack of
further follow-up in one third of the patients, making it
impossible to determine a more precise rate of
recurrences.
The strengths of this study are the number of patients
studied, one of the biggest cohorts published in RF; the
determination of adherence rates to RF secondary pro-
phylaxis in a representative Brazilian cohort; and the
evidence supporting the necessity of a revision of Jones
criteria for areas that still have high incidences of RF, as
pointed out by several other authors.
Conclusion
Based in the high rates of non-adherence to appoint-
ments and secondary prophylaxis, which lead to recur-
rent episodes of RF, we recommend implementation of
a registry, and a system of active search of missing
patients in every service responsible for the follow-up of
RF patients. Measures to increase adherence to second-
ary prophylaxis involving patients and families need to
be implemented formally, once non-adherence to sec-
ondary prophylaxis is the main cause of RF recurrence,
still an issue in many parts of the world. Detection of
irregularity in secondary prophylaxis or in appointments
should be an alert about the possibility of loss of follow-
up and closer observation should be instituted. Caution
in strictly following Jones criteria to diagnose RF in
countries with high incidence of the disease, as in Brazil,
is recommended.
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